Relationship between aetiology and left ventricular systolic dysfunction in hypertrophic cardiomyopathy. by Rosmini, S et al.
1 
 
 
Relationship between aetiology and left ventricular systolic dysfunction in 
hypertrophic cardiomyopathy 
Stefania Rosmini, MD, PhD1,2, Elena Biagini, MD, PhD2, Costantinos O'Mahony, MD, PhD1, 3, 
Heerajnarain Bulluck, MD1, 3, Niccolo’ Ruozi, MD2, Luis R Lopes, MD, PhD3,4,5, Oliver Guttmann, 
MD1, 3, Patricia Reant, MD, PhD6, Cristina C. Quarta, MD, PhD7, Antonis Pantazis, MD3, Maria 
Tome-Esteban, MD3, William J Mckenna, MD3, Claudio Rapezzi, MD 2, Perry M. Elliott, MD 1,3. 
 
1Centre for Inherited Cardiovascular Diseases, St Bartholomew’s Hospital, West Smithfield, London. 
2Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Alma Mater Studiorum-
University of Bologna, Italy. 3 Institute of Cardiovascular Science, University College London, UK. 
4Cardiovascular Centre, University of Lisbon, Lisbon, Portugal. 5Cardiology Department, Hospital Garcia de 
Orta, Almada, Portugal. 6University of Bordeaux, University Hospital of Bordeaux, Bordeaux, France. 
7National Amyloidosis Centre, Royal Free Hospital, London, UK. 
 
Word count: 2601 
 Key words: hypertrophic cardiomyopathy, phenocopies, systolic dysfunction, prognosis.  
 
Address for correspondence:   
Professor Perry M Elliott 
Centre for Inherited Cardiovascular Diseases 
2 
 
University College London & St Bartholomew’s Hospital, 
West Smithfield   
London EC1A 7BE 
Email: perry.elliott@ucl.ac.uk  
Phone number: 020 3416 5000 
 
 
  
3 
 
Abstract   
Background: Severe left ventricular (LV) systolic dysfunction is an uncommon complication of 
hypertrophic cardiomyopathy (HCM) that is associated with poor prognosis. Small observational 
series suggest that patients with rare causes of HCM are more likely to develop systolic 
impairment than those with idiopathic disease or mutations in cardiac sarcomeric protein genes.  
The aim of this study was to test this hypothesis by comparing the prevalence of systolic 
dysfunction and its impact on prognosis in patients with different causes of HCM. 
Methods and Results: 1697 patients [52 (40-63) years, 1160 (68%) males] with HCM followed at 
two European referral centres were studied. Diagnosis of specific aetiologies was made on the 
basis of clinical examination, cardiac imaging and targeted genetic and biochemical testing. The 
primary survival outcome was all-cause mortality or heart transplantation (HTx) for end-stage 
heart failure. Secondary outcomes were heart failure (HF)-related death, sudden cardiac death, 
stroke-related death, and non-cardiovascular (CV) death.  
Systolic dysfunction (LV ejection fraction <50% by 2D-echocardiography) at first evaluation 
was more frequent in rare phenocopies than in idiopathic or sarcomeric HCM [105/409 (26%) 
versus 40/1288 (3%), respectively (p<0.0001)]. All-cause death/HTx and HF-related death was 
more frequent in rare phenocopies compared to idiopathic or sarcomeric HCM, (p<0.0001). All-
cause mortality and HF-related death was highest in patients with cardiac amyloidosis, (p<0.0001). 
Conclusions: In adults with HCM, LV systolic dysfunction is more frequent in those with rare 
phenocopies. When combined with age at presentation, it is a marker for specific aetiologies and 
is associated with poorer long-term survival.  
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What is already known about this subject? 
Hypertrophic cardiomyopathy (HCM) is a generic term that encompasses a number of different 
diseases. Left ventricular (LV) systolic dysfunction is an uncommon complication of the disease, 
but its relation to underlying aetiology has not been investigated. Similarly, there are no studies in 
literature investigating the impact of aetiology on long term prognosis in large populations of 
patients with HCM.   
 
What does this study add?  
This study shows that LV systolic dysfunction at first evaluation is more frequent in rare HCM 
phenocopies than in disease caused by mutations in cardiac sarcomeric protein gene mutations 
(the commonest cause of HCM). The causes of systolic LV dysfunction varied with age in that there 
was a higher prevalence of syndromic and metabolic diseases in the young, whereas cardiac 
amyloidosis was exclusively seen in older age groups. The underlying aetiology also influenced 
survival with rare phenocopies–in particular cardiac amyloidosis–being associated with a poor 
long-term survival. 
 
How might this impact on clinical practice?  
These findings show that systolic LV dysfunction in patients with HCM is a diagnostic clue that 
should prompt a systematic search for rarer phenocopies informed by the age of the patient at 
first presentation.  These rare conditions are important because they have prognostic implications 
and can be overlooked or misdiagnosed if the index of clinical suspicion is low.   
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Hypertrophic cardiomyopathy (HCM) is a common cardiac disease caused by a number of genetic 
and acquired disorders [1]. Mutations in genes coding for cardiac sarcomeric proteins account for 
the majority of cases, but other diseases including inherited disorders of metabolism, myocardial 
infiltration, neuromuscular disorders and malformation syndromes can present with a similar 
phenotype. In many cases, obvious clinical features suggest the diagnosis of these less common 
disorders, but in some patients they may be overlooked or misdiagnosed if the index of clinical 
suspicion is low. 
Severe left ventricular (LV) systolic dysfunction, commonly referred to as end-stage disease 
or the “burnt-out phase”, is an uncommon but important evolution of idiopathic or sarcomeric 
HCM [2-5]. In tertiary referral centres, end-stage disease has a prevalence of 2-5% and an 
incidence of 0.5-1 cases per 100 patient years and is associated with a poor prognosis due to high 
rates of refractory heart failure and sudden arrhythmic death [3-7]. Small observational series 
suggest that patients with some of the rarer HCM phenocopies are more likely to develop systolic 
impairment than those with disease caused by sarcomeric protein gene mutations [8-12] and 
current ESC guidelines suggest that LV systolic dysfunction is one of several clinical features that 
assist in the differential diagnosis of HCM [13]. The aim of this study was to test this hypothesis by 
comparing the prevalence of systolic dysfunction in patients with different causes of HCM. A 
secondary aim was to assess the impact of aetiology on long-term survival. 
 
METHODS 
Study design and setting 
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This was a retrospective, longitudinal cohort study involving patients from two European 
cardiomyopathy centres – The Heart Hospital, University College Hospitals Trust, London U.K. and 
Bologna University Hospital, Italy. The study conformed to the principles of the Helsinki 
declaration.  
Study population and patient assessment 
Patients were identified by systematically searching hospital records and clinical databases. 
Patients were evaluated using medical history, pedigree analysis, physical examination, ECG, 
cardiac imaging and laboratory testing. Further specialised tests such as skeletal muscle and 
endomyocardial biopsy, and molecular genetic testing were performed when there were features 
from the pedigree analysis, clinical examination or preliminary investigations that suggested a 
possible rare phenocopy. 
All patients included in the study were ≥16 years of age. HCM was defined as a maximal LV 
wall thickness (MWT) ≥15 mm or ≥13mm in patients with unequivocal familial disease [14] and/or 
a diagnosed rare non-sarcomeric phenocopy.  
The Heart Hospital population comprised a cohort of unrelated consecutive patients with 
idiopathic or sarcomeric HCM who were tested for sarcomeric protein gene mutations using high-
throughput sequencing between 2011 and 2013 [15] and all patients diagnosed with one of the 
following conditions between 1991 and 2014: Anderson-Fabry disease (AFD), primary 
mitochondrial disease, immunoglobulin light chain amyloidosis (AL), hereditary transthyretin type 
amyloidosis (ATTR), wild-type or senile systemic amyloidosis (SSA), Noonan syndrome, LEOPARD 
syndrome (Lentigines, Electrocardiographic abnormalities, Ocular hypertelorism, Pulmonary 
stenosis, Abnormalities of the genitalia, Retardation of growth, Deafness), carnitine 
palmitoyltransferase II (CPT II) deficiency, mutations in the four and a half LIM domain protein 1 
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(FHL1) gene, Friedreich’s ataxia and glycogen storage disease (GSD) including Danon disease and 
AMP-protein kinase deficiency caused by mutations in PRKAG2. 
The cohort from Bologna University Hospital comprised consecutive patients with 
idiopathic or sarcomeric HCM (some of whom have been included in other recently published 
studies) [16-19] and with the same phenocopies as described above assessed between 1980 and 
2013.   
Data collection 
Data were collected independently at each participating centre using uniform methodology. 
Clinical characteristics were assessed at first (baseline) evaluation. LV systolic dysfunction was 
defined as a resting LV ejection fraction <50% measured using 2D echocardiography and the 
biplane Simpson method [5]. 
Study outcomes 
The primary outcome was all-cause mortality or heart transplantation (HTx) for end-stage heart 
failure. Secondary outcomes were as follows: sudden cardiac death, heart failure (HF)-related 
death, stroke-related death, and non-cardiovascular (CV) death. When the cause of death was not 
known, the death was considered non-cardiac in all analyses [20]. The cause of death was 
ascertained at each centre using hospital and primary health care records, death certiﬁcates, post-
mortem reports, and interviews with witnesses.  
Sudden cardiac death was defined as natural death due to cardiac causes, occurring within 
1 hour of the onset of acute symptoms. Death was also classified as sudden if it occurred 
unexpectedly but was unwitnessed, such as in bed overnight. Appropriate implantable 
cardioverter–defibrillator (ICD) intervention for ventricular fibrillation or ventricular tachycardia 
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and aborted cardiac death with successful cardiac resuscitation were considered as equivalent to 
sudden cardiac death. Heart failure-related death included deaths in individuals with symptoms of 
progressive heart failure including cardiogenic shock [20].  
Statistical analysis 
Data are reported as median and interquartile range (IQR) for continuous variables or frequencies 
(percentage) for categorical variables. Comparison of clinical and laboratory variables between 
patient subgroups was performed with 2-sample t-test for continuous parametric variables and 
Mann–Whitney U test for all continuous non-parametric variables. Categorical variables were 
compared using Chi-square test for parametric data. Comparisons of multiple groups of 
continuous non-parametric data were performed using the Kruskall Wallis test.  
The follow-up time for each patient was calculated from the date of their first evaluation at 
each centre to the date of the primary end-point or to the date of their most recent clinical 
evaluation. The cumulative probability for the occurrence of an outcome was estimated using the 
Kaplan-Meier method and log-rank test from the first clinical evaluation at the referral centre.  
All p-values were two-sided and the results were considered statistically significant if < 0.05. SPSS 
(Version 22.0) was used for all statistical analyses.  
 
RESULTS 
The combined study population consisted of 1703 patients. Six patients were excluded as there 
were no verifiable data on LV systolic function. Eight seven per cent of the entire cohort had a wall 
thickness ≥15 mm. Of the remainder, 7% had a family history of HCM caused by a sarcomeric 
protein gene mutation and 6% had rare phenocopies; 74% (304/409) of the phencopies had MWT 
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≥15mm. Figure 1 shows the patient population selection process and Table 1 summarizes the 
different aetiological subgroups at each centre.  
Table 1. Summary of diagnostic subgroups at each centre. 
 Overall 
n=1697 
The Heart Hospital  
n=987 (58%) 
Bologna University 
Hospital 
n=710 (42%) 
Idiopathic or sarcomeric HCM n (%) 1288 (76) 826 (49)   462 (27) 
Phenocopies, n (%) 409 (24) 161 (9) 248 (15) 
AL amyloidosis, n (%) 115 (7) 6 (0.4) 109 (6) 
Hereditary TTR amyloidosis, n (%) 86 (5) 6 (0.4) 80 (5) 
Anderson-Fabry disease (AFD), n (%) 85 (5) 77 (5) 8 (0.5) 
Wild-type or SSA, n (%) 48 (3) 8 (0.5) 40 (2) 
Noonan syndrome, n (%) 15 (1) 11 (0.6) 4 (0.2) 
Mitochondrial diseases, n (%) 23 (1) 21 (1) 2 (0.1) 
Friedreich’s ataxia, n (%) 11 (1) 9 (0.5) 2 (0.1) 
Glycogen storage disease (GSD), n (%) 16 (1) 14 (0.8) 2 (0.1) 
LEOPARD syndrome, n (%) 7 (0.4) 6 (0.4) 1 (0.1) 
FHL1 mutations, n (%) 2 (0.1) 2 (0.1) 0 (0) 
CPT II deficiency, n (%) 1 (0.1) 1 (0.1) 0 (0) 
 
 AFD= Anderson-Fabry disease, AL= immunoglobulin light chain, GSD= glycogen storage disease, 
HCM= hypertrophic cardiomyopathy, LEOPARD= Lentigines, Electrocardiographic abnormalities, 
Ocular hypertelorism, Pulmonary stenosis, Abnormalities of the genitalia, Retardation of growth, 
Deafness, SSA= senile systemic amyloidosis, TTR= transthyretin type. 
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Clinical characteristics at first evaluation 
Demographic and clinical features of patients at first evaluation are described in Table 2.  
Table 2. Clinical and echocardiographic features at first evaluation. 
 Overall 
(n=1697) 
Idiopathic or 
sarcomeric HCM  
(n=1288) 
Rare 
phenocopies 
(n=409) 
p 
Male, n (%) 1160 (68) 860 (67) 300 (73) 0.012 
Reason for diagnosis 
  Incidental, n (%) 
  Cardiac symptoms, n (%) 
  Family screening, n (%) 
  One or more non cardiac symptoms, n (%) 
 
475 (29) 
822 (51) 
180 (11) 
140 (9) 
 
437 (36) 
660 (54) 
128 (10) 
0 (0) 
 
38 (10) 
162 (41) 
52 (13) 
140 (35) 
 
 
 
<0.0001 
Age at diagnosis of HCM, median (IQR) 50 (38-62) 49 (37-60) 58 (44-69) <0.0001 
Age at first evaluation, median (IQR) 52 (40-63) 51 (39-61) 60 (47-69) <0.0001 
NYHA III-IV at first evaluation, n (%) 241 (14) 144 (11) 97 (24) 0.013 
Rhythm at first evaluation, n (%) 
     Sinus rhythm 
     Atrial fibrillation/Atrial flutter 
     Paced  
 
1461 (89) 
124 (8) 
53 (3) 
 
1124 (87) 
74 (6) 
33 (3) 
 
337 (82) 
50 (12) 
20 (5) 
 
 
<0.0001 
Max LVWT at first evaluation, (mm), 
median (IQR) 
18 (16-21) 18 (16-22) 16 (14-19) <0.0001 
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LVED diameter at first evaluation, (mm), 
median (IQR) 
45 (41-49) 45 (41-49) 45 (40-49) 0.145 
EF at first evaluation, (%), median (IQR) 65 (57-71) 66 (60-72) 60 (48-68) <0.0001 
EF <50% at first evaluation, n (%) 145 (9) 40 (3) 105 (26) <0.0001 
LA diameter at first evaluation, (mm), 
median (IQR) 
44 (39-49) 44 (40-49) 44 (38-48) 0.072 
EF= ejection fraction, HCM= hypertrophic cardiomyopathy, IQR= interquartile range, LA= left 
atrium, LVED= left ventricular end diastolic, LVWT= left ventricular wall thickness, NYHA=New York 
Heart Association functional class. 
 
Patients with rare phenocopies were more often diagnosed because of one or more non-cardiac 
symptoms [140 (35%) versus 0 (0%), p<0.0001] and were more symptomatic at first evaluation 
[NYHA functional class III-IV 97 (24%) versus 144 (11%), p=0.013] than patients with idiopathic 
HCM or HCM caused by sarcomeric protein gene mutations.  
 
Prevalence of LV systolic impairment  
Systolic impairment was present in 145 patients (9%).  The prevalence of systolic impairment was 
higher in patients with rare phenocopies compared to patients with idiopathic or sarcomeric HCM 
(Table 2).  
The prevalence of LV systolic dysfunction amongst patients with rare phenocopies was 
highest in patients with AL amyloidosis (40%, 46/115 patients) followed by SSA (38%, 18/48 
patients), GSD (31%, 5/16 patients, 3 with PRKAG2 mutation), hereditary TTR amyloidosis (28%, 
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24/86 patients), Friedreich’s ataxia (18%, 2/11 patients), mitochondrial disease (13%, 3/23 
patients) and AFD (8%, 7/85 patients). None of the patients with a diagnosis of Noonan syndrome, 
LEOPARD syndrome, FHL1 or CPT II deficiency showed LV systolic impairment at first evaluation. In 
the overall population, one patient with idiopathic HCM had undergone septal myectomy and no 
patient had a previous alcohol septal ablation. 
 
Age at first evaluation according to aetiology  
Idiopathic or sarcomeric HCM was the most frequent diagnosis at all ages. Other disorders were 
distributed across all decades with a higher prevalence for syndromic and metabolic diseases in 
the young and cardiac amyloidosis in older age groups. Median age at first evaluation was lowest 
in patients with Friedreich’s ataxia [20 (17-23) years), LEOPARD syndrome [23 (19-63) years],  
Noonan syndrome [24 (20-40) years] and GSD [24 (22-40) years] and highest in patients with 
hereditary TTR amyloidosis [59 (47-66) years], AL amyloidosis [63 (56-69) years] and wild-type or 
SSA [78 (72-81) years] (Figure 2). A similar age distribution was seen in patients with LV systolic 
dysfunction (Figure 3). 
 
Prognosis in relation to aetiology and LV systolic function  
Median duration of follow-up from first evaluation was 3.7 (IQR 1.6-7.2) years. In the overall 
population, 58 patients were assessed only at first evaluation and therefore were excluded from 
the outcome analysis. Two hundred and fifty (15%) patients died or underwent orthotopic heart 
transplantation. Death from any cause and heart transplantation were more frequent in rare 
phenocopies compared to idiopathic or sarcomeric HCM [129 (33%) versus 121 (10%), respectively 
(p<0.0001)] (Figure 4A). Similar results were found for heart failure-related death [34 (9%) versus 
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21 (2%), respectively (p<0.0001) (Figure 4B). All-cause mortality, CV death, death from heart 
failure and heart transplantation were all more common in patients with rare phenocopies 
compared to patients with idiopathic or sarcomeric HCM or non-syndromic HCM (Table 3).  
 
Table 3. Outcomes in the overall population, idiopathic or sarcomeric HCM and in rare 
phenocopies. 
 Overall 
population 
(1639 pts) 
Idiopathic or 
sarcomeric HCM 
(1243 pts) 
Rare 
Phenocopies 
(396 pts) 
p 
All-cause mortality/HTx n (%) 250 (15) 121 (10) 129 (33) <0.0001 
CV death/HTx, n (%) 160 (10) 89 (7) 71 (18) <0.0001 
HF death, n (%) 55 (3) 21 (2) 34 (9) <0.0001 
HTx, n (%) 33 (2) 18 (1) 15 (4) 0.006 
SD, n (%)  60 (4) 41 (3) 19 (5)  
 
<0.0001 
Stroke-related death, n (%) 11 (1) 9 (1) 2 (0.5) 
Non-CV death, n (%) 46 (3) 26 (2) 20 (5) 
Unknown, n (%) 50 (3) 6 (0.5) 44 (11) 
HCM= hypertrophic cardiomyopathy, CV= cardiovascular, HF= heart failure, HTx= heart 
transplantation, SD= sudden death 
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Thirteen (9%) of the 145 patients with systolic impairment underwent heart transplantation.  
Kaplan Meier analysis demonstrated that all-cause mortality/heart transplantation and heart 
failure-related mortality were highest in patients affected by cardiac amyloidosis (Figure 5A and 
B). Heart failure-related deaths only occurred in patients with cardiac amyloidosis (n=21), 
idiopathic or sarcomeric HCM (n=21) and AFD (n=4). All-cause death/heart transplantation and 
death from heart failure were more frequent in patients with LV systolic dysfunction than in 
patients with preserved LV systolic function, (p<0.0001). No gender differences were present for 
any analyses. 
 
DISCUSSION 
To the best of our knowledge, this is the first study to assess the prevalence of LV systolic 
dysfunction in adult patients with HCM caused by different aetiologies. The recent ESC guidelines 
suggest that LV systolic impairment should be considered as diagnostic ‘red flag’ for less common 
causes of otherwise unexplained LV hypertrophy [1]. Our study confirmed this hypothesis, 
showing that LV systolic dysfunction is more frequent in rarer phenocopies compared to idiopathic 
or sarcomeric hypertrophic cardiomyopathy. Moreover, the prevalence of different phenocopies is 
age dependent. 
 
Relation between aetiology and age at presentation 
The starting point in this study was a clinical diagnosis of HCM based on LV wall thickness [1]. 
While HCM is most commonly an inherited disease caused by mutations in genes encoding 
sarcomeric proteins, approximately 5-10% of patients have rarer disorders which may be 
overlooked unless they are specifically excluded. In the most recent ESC guideline on HCM [1], 
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great emphasis is placed on the search for diagnostic clues or ‘red flags’ that point towards one of 
these phenocopies. This study shows that one of the most important of these diagnostic pointers 
is the age at presentation, as many phenocopies manifest predominantly in early, middle or late 
decades of life. In some instances, presentation is confined to particular age ranges; for example, 
wild type TTR amyloidosis in the elderly and Friedreich’s ataxia in the young. 
 
Systolic function in relation to aetiology 
In most patients with idiopathic or sarcomeric HCM, LV systolic function measured using ejection 
fraction is within or above normal ranges due to a small LV cavity and preserved radial function, 
but several studies have shown that some patients develop progressive systolic impairment during 
follow-up. The prevalence of severe systolic impairment (arbitrarily defined as an EF of < 50%) 
using conventional echocardiographic criteria ranges from 2% to nearly 5%, with an annual 
incidence of less than 1% [3-5]. This so-called end-stage disease can develop at any age, but in the 
majority of patients, the time from onset of symptoms to diagnosis of severe systolic impairment 
is about 10-15 years [3]. The development of severe systolic heart failure is associated with a poor 
prognosis, with rapid progression to death or transplantation and a mortality of up to 11% per 
year [5].  
In this study, the prevalence of severe LV systolic impairment was nine times higher in 
patients with rare phenocopies compared to patients with idiopathic or sarcomeric HCM. Just as 
with the aetiology of HCM, the clinical profile of patients with systolic impairment varied with age 
in that Friedreich’s ataxia and GSD showed the earliest presentation with systolic impairment 
compared to patients with mitochondrial disease, AFD and wild-type amyloidosis in whom systolic 
impairment was a late event. None of the patients with a diagnosis of Noonan syndrome, 
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LEOPARD syndrome, FHL1 mutations or CPT II deficiency showed LV systolic impairment at first 
evaluation.  
Impact of systolic dysfunction on prognosis 
During follow-up, the rate of death and heart transplantation was three times higher in patients 
with rare phenocopies than in patients with idiopathic or sarcomeric HCM due to a much higher 
incidence of death from progressive heart failure. This finding was driven predominantly by 
patients with AL and TTR related amyloidosis who had the poorest survival among all the patient 
subgroups, a finding consistent with the known natural history of these diseases [21-23]. The 
overall rate of heart transplantation was low in the total study cohort, but was performed in 
almost 10% of patients with systolic impairment at first evaluation, highlighting the need for close 
monitoring of this cohort. 
 
Clinical Implications 
The term hypertrophic cardiomyopathy embraces a wide range of conditions with different 
natural histories and prognosis. This study shows that the presence of severe systolic impairment 
should prompt a systematic search for rare phenocopies informed by the age of the patient at first 
presentation. The implications for individual patients vary according to the underlying disease, but 
in some cases disease-specific therapies that impact on morbidity and prognosis are available. In 
patients without rare phenocopies, regular monitoring for symptomatic deterioration and 
progressive heart failure should be performed. 
 
CONCLUSION 
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In an adult population of patient with HCM, LV systolic dysfunction is more frequent in rare causes 
of HCM. When combined with age at presentation it is a marker for specific aetiologies and is 
associated with poorer long-term survival.  
 
Limitations  
The aim of our study was not to explore the prevalence of the different diseases underlying the 
hypertrophic phenotype, but rather to explore the clinical relevance of LV systolic dysfunction in 
different HCM phenocopies.   
The population in this study is heterogeneous in relation to genetic analysis (the UK population 
being represented by patients consecutively investigated by next generation sequencing while in 
the Italian population classic genetic analysis by Sanger was performed on case-by-case basis). 
Therefore no statistical analysis on the impact of genotype has been performed. 
Data collection in the two participating centres took place over very different time periods and 
could have affected outcomes due to changes in treatment regimens, particularly for patients with 
amyloidosis. 
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FIGURE LEGENDS 
Figure 1. Patient population selection process. 
This figure illustrates the selection process and number of patients in each etiological subgroup. *3 
patients with Danon disease and 5 pts with AMP-protein kinase deficiency or PRKAG2.  
AFD= Anderson-Fabry disease, AL= immunoglobulin light chain, CPT II= carnitine 
palmitoyltransferase II, EF= ejection fraction, FH= family history, FHL1= Four and a Half LIM 
domain protein 1, GSD= glycogen storage disease, HCM= hypertrophic cardiomyopathy, 
LEOPARD= Lentigines, Electrocardiographic abnormalities, Ocular hypertelorism, Pulmonary 
stenosis, Abnormalities of the genitalia, Retardation of growth, Deafness, SSA= senile systemic 
amyloidosis, TTR= transthyretin type. 
Figure 2. Age at first evaluation according to main aetiologies in the overall population. 
Distribution of median age at first evaluation: this was lowest in patients with Freidreich’s ataxia, 
LEOPARD syndrome, Noonan syndrome and GSD and highest in patients with hereditary TTR 
amyloidosis, AL amyloidosis and wild-type or SSA. The box represents the interquartile range (IQR) 
and the line across the box indicates the median. The whiskers represent the highest and lowest 
values which are no greater than 1.5*IQR from the upper or lower edge of the box. In brackets 
number of patient in each group/percentage. Abbreviations as in Figure 1.  
Figure 3. Age at first evaluation according to aetiology in patients with LV systolic dysfunction. 
Distribution of median age at first evaluation according to aetiology in patients with LV systolic 
dysfunction (145 patients). Abbreviations as in Figure 1.  Graph explanation as in Figure 2.  
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Figure 4. Outcomes in patients with idiopathic or sarcomeric HCM versus those with rare 
phenocopies. 
Cumulative incidence of All-cause mortality or HTx (A) and HF-related death (B) in idiopathic or 
sarcomeric HCM versus phenocopies. Number at risk at each time point displayed on the x-axis. 
HCM=hypertrophic cardiomyopathy, HF=heart failure, HTx= heart transplantation. 
Figure 5. Outcomes in idiopathic or sarcomeric HCM compared with specific rare phenocopies. 
Cumulative incidence of All-cause mortality or HTx (A) and HF-related death (B) according to 
specific aetiologies. Number at risk at each time point displayed on the x-axis. Abbreviations as in 
Figure 4. AFD= Anderson-Fabry disease, AL= immunoglobulin light chain, HCM= hypertrophic 
cardiomyopathy, HF=heart failure, HTx= heart transplantation, SSA= senile systemic amyloidosis.  
 
